Basal-bolus insulin therapy during switching over from continuous intra venous regular insulin to sub cutaneous insulin therapy as compared to conventional regimens in type-2 diabetes patients admitted

Subrata Halder, Priyankar Biswas, Debasis Sarkar, Bikram Kr. Saha


Background: According to the World Health Organization (WHO), over 347 million people worldwide have diabetes. Latest estimates reveal that 25.4 million Americans have diabetes mellitus (DM), with up to 95% of those having type 2 DM. This study was done to know the effects of Glargine insulin plus human regular insulin on blood sugar control while switching over from continuous IV insulin infusion to SC route as compared to conventional SC insulin regimens in CCU setup.

Methods: 65 patients of T2DM were included this study. Detailed history, physical examination and relevant systemic examination were performed and necessary lab investigations were done.

Results: The mean age was 49.52±10.16. Mean FPG on 1st Day: The p value of B-B against PRE is significant. Mean FPG on Day of discharge: The p value of B-B against PRE is significant and B-B against NPH is also significant. Mean FPG 2Weeks after discharge: The p value of B-B against PRE is significant and B-B against NPH is also significant. Mean PPPG on 1st Day: The p value of B-B against NPH is significant. Mean PPPG on day of discharge: The p value of B-B against PRE is significant. Mean PPPG 2weeks after discharge: The p value of B-B against PRE is significant. Hypoglycemia was occurring in 25, 15, and 25 in BB, NPH, and PRE group respectively. The p value is significant when NPH compared to PRE.

Conclusions: B-B regimen was better than other regimen for controlling FPG and PPPG. The insulin dose was high in NPH regimen compared to both B-B and PRE regimens. 



T2DM, Fasting plasma glucose, Post prandial plasma glucose, Basal- bolus, NPH, Premix insulin, Hypoglycemia

Full Text:



Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125:473-82.

Moghissi ES1, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American association of clinical endocrinologists and american diabetes association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-31.

Umpierrez GE1, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non‑critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16‑38.

Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: A clinical practice guideline from the American college of physicians. Ann Intern Med. 2011;154:260‑7.

NICE‑SUGAR Study Investigators, Finfer S, Liu B et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108‑18.

Umpierrez GE, Smiley D et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30:2181-6.

van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. New England Journal of Medicine. 2001;345(19):1359-67.

Deno K, Schaper J. Glucose control in the medical patient: Bolus insulin dosing compared to basal-bolus insulin dosing. MEDSURG Nursing. 2011;20(5):217-234. PMid:22165780

Clement S1, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-591.

Umpierrez GE, Isaacs SD. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-82.

Vasan SK, Pittard AE. Cause-specific mortality in diabetes: retrospective hospital based data from south India. J Diabetes. 2012;4:47-54.

Riddle MC, Rosenstock J. Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6.

Rosenstock J, Fonseca V: Similar progression of diabetic retinopathy with insulin glargine and neutral protamineHagedorn (NPH) insulin in patients with type 2diabetes: a long-term, randomised, open-label study. Diabetologia. 2009;52:1778-88.

Yki-Ja¨ rvinen H, Kauppinen-Ma: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-51.

Fritsche A, Schweitzer MA. 4001 Study Group:Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulinglargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952-9.

Raskin P, Allen E. Initiate study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic andbasal insulin analogs. Diabetes Care. 2005;28:260-5.

Janka HU, Plewe G: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-9.

Holman RR, Farmer AJ: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-47

Buse JB, Wolffenbuttel BH. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32:1007-13.